455 related articles for article (PubMed ID: 11213096)
1. Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhoea.
Kyne L; Warny M; Qamar A; Kelly CP
Lancet; 2001 Jan; 357(9251):189-93. PubMed ID: 11213096
[TBL] [Abstract][Full Text] [Related]
2. Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A.
Kyne L; Warny M; Qamar A; Kelly CP
N Engl J Med; 2000 Feb; 342(6):390-7. PubMed ID: 10666429
[TBL] [Abstract][Full Text] [Related]
3. Association between IgG2 and IgG3 subclass responses to toxin A and recurrent Clostridium difficile-associated disease.
Katchar K; Taylor CP; Tummala S; Chen X; Sheikh J; Kelly CP
Clin Gastroenterol Hepatol; 2007 Jun; 5(6):707-13. PubMed ID: 17544998
[TBL] [Abstract][Full Text] [Related]
4. Serum anti-toxin B antibody correlates with protection from recurrent Clostridium difficile infection (CDI).
Leav BA; Blair B; Leney M; Knauber M; Reilly C; Lowy I; Gerding DN; Kelly CP; Katchar K; Baxter R; Ambrosino D; Molrine D
Vaccine; 2010 Jan; 28(4):965-9. PubMed ID: 19941990
[TBL] [Abstract][Full Text] [Related]
5. Systemic antibody responses induced by a two-component Clostridium difficile toxoid vaccine protect against C. difficile-associated disease in hamsters.
Anosova NG; Brown AM; Li L; Liu N; Cole LE; Zhang J; Mehta H; Kleanthous H
J Med Microbiol; 2013 Sep; 62(Pt 9):1394-1404. PubMed ID: 23518659
[TBL] [Abstract][Full Text] [Related]
6. Human antibody response to surface layer proteins in Clostridium difficile infection.
Drudy D; Calabi E; Kyne L; Sougioultzis S; Kelly E; Fairweather N; Kelly CP
FEMS Immunol Med Microbiol; 2004 Jul; 41(3):237-42. PubMed ID: 15196573
[TBL] [Abstract][Full Text] [Related]
7. Human monoclonal antibodies directed against toxins A and B prevent Clostridium difficile-induced mortality in hamsters.
Babcock GJ; Broering TJ; Hernandez HJ; Mandell RB; Donahue K; Boatright N; Stack AM; Lowy I; Graziano R; Molrine D; Ambrosino DM; Thomas WD
Infect Immun; 2006 Nov; 74(11):6339-47. PubMed ID: 16966409
[TBL] [Abstract][Full Text] [Related]
8. Role of antibody response in outcome of antibiotic-associated diarrhoea.
Wilcox M; Minton J
Lancet; 2001 Jan; 357(9251):158-9. PubMed ID: 11213086
[No Abstract] [Full Text] [Related]
9. Humoral immune response as predictor of recurrence in Clostridium difficile infection.
Bauer MP; Nibbering PH; Poxton IR; Kuijper EJ; van Dissel JT
Clin Microbiol Infect; 2014 Dec; 20(12):1323-8. PubMed ID: 25041274
[TBL] [Abstract][Full Text] [Related]
10. Association of interleukin-8 polymorphism and immunoglobulin G anti-toxin A in patients with Clostridium difficile-associated diarrhea.
Jiang ZD; Garey KW; Price M; Graham G; Okhuysen P; Dao-Tran T; LaRocco M; DuPont HL
Clin Gastroenterol Hepatol; 2007 Aug; 5(8):964-8. PubMed ID: 17618838
[TBL] [Abstract][Full Text] [Related]
11. Immunoglobulin G directed against toxins A and B of Clostridium difficile in the general population and patients with antibiotic-associated diarrhea.
Bacon AE; Fekety R
Diagn Microbiol Infect Dis; 1994 Apr; 18(4):205-9. PubMed ID: 7924215
[TBL] [Abstract][Full Text] [Related]
12. Systemic and mucosal antibody responses to toxin A in patients infected with Clostridium difficile.
Johnson S; Gerding DN; Janoff EN
J Infect Dis; 1992 Dec; 166(6):1287-94. PubMed ID: 1431247
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the premier toxin A and B assay and the TOX A/B II assay for diagnosis of Clostridium difficile infection.
Novak-Weekley SM; Hollingsworth MH
Clin Vaccine Immunol; 2008 Mar; 15(3):575-8. PubMed ID: 18175802
[TBL] [Abstract][Full Text] [Related]
14. Immunisation of mares with binding domains of toxins A and B of Clostridium difficile elicits serum and colostral antibodies that block toxin binding.
Artiushin S; Timoney JF; Fettinger M; Fallon L; Rathgeber R
Equine Vet J; 2013 Jul; 45(4):476-80. PubMed ID: 23206274
[TBL] [Abstract][Full Text] [Related]
15. Antigenicity of amino-acid sequences from Clostridium difficile toxin B.
Torres JF; Monath TP
J Med Microbiol; 1996 Jun; 44(6):464-74. PubMed ID: 8636964
[TBL] [Abstract][Full Text] [Related]
16. Development of a recombinant toxin fragment vaccine for Clostridium difficile infection.
Karczewski J; Zorman J; Wang S; Miezeiewski M; Xie J; Soring K; Petrescu I; Rogers I; Thiriot DS; Cook JC; Chamberlin M; Xoconostle RF; Nahas DD; Joyce JG; Bodmer JL; Heinrichs JH; Secore S
Vaccine; 2014 May; 32(24):2812-8. PubMed ID: 24662701
[TBL] [Abstract][Full Text] [Related]
17. Mechanisms of protection against Clostridium difficile infection by the monoclonal antitoxin antibodies actoxumab and bezlotoxumab.
Yang Z; Ramsey J; Hamza T; Zhang Y; Li S; Yfantis HG; Lee D; Hernandez LD; Seghezzi W; Furneisen JM; Davis NM; Therien AG; Feng H
Infect Immun; 2015 Feb; 83(2):822-31. PubMed ID: 25486992
[TBL] [Abstract][Full Text] [Related]
18. Sensitive assays enable detection of serum IgG antibodies against Clostridium difficile toxin A and toxin B in healthy subjects and patients with Clostridium difficile infection.
Zhao X; Bender F; Shukla R; Kang JJ; Caro-Aguilar I; Laterza OF
Bioanalysis; 2016 Apr; 8(7):611-23. PubMed ID: 26964649
[TBL] [Abstract][Full Text] [Related]
19. Colonic IgA producing cells and macrophages are reduced in recurrent and non-recurrent Clostridium difficile associated diarrhoea.
Johal SS; Lambert CP; Hammond J; James PD; Borriello SP; Mahida YR
J Clin Pathol; 2004 Sep; 57(9):973-9. PubMed ID: 15333661
[TBL] [Abstract][Full Text] [Related]
20. Development of a new serological assay for the diagnosis of Clostridium difficile infections with prognostic value.
von Bechtolsheim F; Varga A; Szereday L; Polgar B; Balassa T; Kocsis B; Peterfi Z; Miko E
J Microbiol Methods; 2019 Dec; 167():105777. PubMed ID: 31733265
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
